



PRESS RELEASE

OPHTHALMOLOGY: NEW EYE DROPS FROM NTC AVAILABLE FOR MORE PATIENTS WORLDWIDE

The fixed combination of levofloxacin and dexamethasone eye drops developed by NTC is now available in Mexico and South-East Asia (Thailand, Singapore, Philippines, Hong Kong)

To date, it is approved by regulatory authorities in more than 40 countries globally, and marketing rights have been granted by the company in more than 80 countries

Milan, 26th October 2022 - NTC Srl, R&D driven pharmaceutical company with headquarters in Italy, announces the registration in Mexico and South-East Asia (Thailand, Singapore, Philippines, Hong Kong) of the first fixed combination in eye drops of a quinolone antibiotic - levofloxacin - and a steroidal anti-inflammatory - for the management of post-cataract.

“The ability to bring Italian innovation internationally thanks to partnership with global leading players is our main goal.” refers Riccardo Carbucicchio, CEO of NTC, “NTC is engaged in a large development and clinical program on several products, meant, in particular, to reduce the antibiotic exposure to patients and to improve compliance for a better therapeutic outcome in ophthalmology”.

To date, the combination developed by NTC with the support of Italian ophthalmologists is registered in over 40 countries globally, and marketing rights have been granted by the company in more than 80 countries.

ntc S.r.l. Con Socio Unico

Sede operativa
Via dei Gracchi, 35
20146 Milano
Italia

Sede legale
via Luigi Razza, 3
20124 Milano
Italia

Tel. +39 02 438 504 1
Fax +39 02 444 032 75

Pec: ntc@legalmail.it
E-mail: info@ntcpharma.com

REG. IMP. MI. / C.F. / P.IVA:
03503980967
R.E.A.:1680028
Capitale sociale € 8.000.000,00 i.v.

Società soggetta ad attività di
direzione e di coordinamento
da parte di Valenmedica S.p.a. - MI